Company intelligence / Profile preview
Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Ownership
- Private
- Employees
- ~5961
- Development stage
- Other
Overview
Guizhou Bailing has a broad portfolio of approved traditional Chinese medicines for cardiovascular/cerebrovascular conditions and respiratory illnesses. Its main products are widely used in China with several holding significant market share within their categories. The company also has at least one product candidate in Phase III clinical development for diabetic retinopathy.
- Therapeutic areas
- CardiovascularOtherWomen's HealthNeurologyInfectious Diseases
- Modalities
- Herbal medicinessmall molecule drugstraditional Chinese medicine formulations (tablets, capsules, syrups, granules, pills, powders, sprays, creams, injections)
- Industry
- Biotech
Drug pipeline
29 assets28 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Guizhou Bailing Group Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guizhou Bailing Group Pharmaceutical Co., Ltd..